Aug 15
Opportunity
Participants expect a simple and convenient experience participating on clinical trials. To accomplish this goal, sponsors should consider the type, design and delivery of device (e.g., personal device, provided by study, etc.) for participants to achieve accessibility, flexibility, convenience and maintain privacy.
Considerations to Help Action the Opportunity
- Understand if the clinical trial design supports the applications of digital patient solutions
- Understand the needs and preferences of the participants taking part in the trial
- Does the population have access to devices and data plans, or would they need these to be provisioned?
- What devices would participants already have that could be used for clinical trials (e.g., wearables / sensors, glucometers, weighing scales, phones / tablets, etc.)?
- Understand impact on health equity (i.e., geographic, socioeconomic barriers) when implementing digital solutions
- Partner with sites to gain their input on the impact of multiple services, training, and technology implementation
- Understand how the device may impact data integrity, regulatory landscape, site implementation and overall costs
- Define how technology is designed, communicated and delivered for / to participants
- Define backup options (e.g., when a participant is unable to connect to device)
Value and Potential Benefits
- Increases access and ease of participation for participants on clinical trials by potentially reducing the number of site visits
- Allows for more robust datasets with improved data compliance and quality by enabling direct entry and near real-time review of data
Related Blog Posts
Why the biggest gains in clinical R&D won’t come from technology
Every few years, the clinical research industry rallies around a new wave of innovation. From decentralised trials and digital biomarkers to AI driven automation, each wave brings genuine capability andpromise. Read the full article featuring Kelsey Jakee on page 38 here.
Enough, already: the problem with clinical trial data collection
The clinical research ecosystem has never been more technologically capable — or more burdened by its own ambition. In December 2025, the Tufts Center for the Study of Drug Development and our team at TransCelerate published research that suggests nearly 30% of the data collected in clinical trials do not directly inform key decisions, yet patients are…
2026 DIA Global Annual Meeting: What the FDA’s Real-Time Data Push Actually Means for Sponsors and CROs
In this video interview from the 2026 DIA Global Annual Meeting, Kevin Bugin, head of global regulatory policy and intelligence at Amgen and executive sponsor of TransCelerate’s Embedded Pragmatic Trials initiative, reframes the FDA’s continuous review expectations around real-time evidence generation and explains why quality by design—not data cleanup—is what regulators are now demanding. Watch…
